drugset
drugset / Trial / NCT03932513

Evaluating the Effects of Inarigivir on Immune Response and Viral Markers in Chronic Hepatitis B Patients

NCT03932513 ↗

Phase 2 Terminated 8 enrolled F-star Therapeutics, Inc. CSI Medical Research Pte Ltd · collab
RandomizedParallel-groupOpen-labelTreatment

Summary

A single center, open-label, study to evaluate the intra-hepatic effect of inarigivir dose per day and three times per week on immune response and viral markers in virally suppressed patients with chronic hepatitis B infection

Timeline

Start
2019-04-11
Primary completion
2019-12-21
Completion
2019-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Inarigivir soproxil Small molecule 400 mg Oral

Indications

chronic hepatitis B virus infection